Dr. David A.H. Whiteman, FAAP, FACMG of Shire has been named vice-president of the ACMG Foundation for Genetic and Genomic Medicine Board of Directors, the supporting educational foundation of the American College of Medical Genetics and Genomics. The ACMG Foundation is a national nonprofit foundation dedicated to facilitating the integration of genetics and genomics into medical practice. The board members are active participants in serving as advocates for the Foundation and for advancing its policies and programs.
Dr. Whiteman will succeed C. Scott Palubiak, MBA who served on the ACMG Foundation Board from 2007 to 2017 and as vice-president of the ACMG Foundation Board from 2012 to 2017.
"We are very grateful to Dr. Palubiak for his longstanding service to the ACMG Foundation. He has played a key role in organizing and supporting the Day of Caring event at our annual meeting and has provided critical input and support in his role as vice-president of the Foundation. We are fortunate that Dr. David Whiteman has accepted a new role on the Foundation board as vice-president. Since joining the board in 2014, he has been actively involved in many initiatives, especially the transformational Shire Training Award that was initiated this past year," said Bruce R. Korf, MD, PhD, FACMG, president of the ACMG Foundation.
Dr. Whiteman said, "I am very pleased to have been given this opportunity to help drive the ACMG Foundation's efforts in support of the ACMG's core mission, especially with regard to genetics education, and to the development of the next generation of laboratory and clinical scientists in medicine."
Dr. Whiteman, currently Global Clinical Development Lead, joined Shire 12 years ago as Medical Director of the Elaprase development program; and subsequently served as Principal Medical Director in the newly developing Global Medical Affairs department at Shire HGT. From 2012 to 2015 at Shire he was Global Medical Lead in Clinical Sciences, providing clinical assessment of new opportunities for the Business Development function; strategic assessment, including rare disease drug development policy and strategy and management of sponsored research related to newborn screening for R&D; and throughout his tenure has been a company-wide resource in drug development, medical genetics and rare diseases.
Dr. Whiteman obtained his undergraduate and medical degrees from Oxford University. Following general postgraduate medical training in Britain, he undertook a residency in Pediatrics in the USA(University of Connecticut Hospitals) and then a clinical and research fellowship in Medical Genetics and Metabolic Diseases at the University of Pennsylvania/Children's Hospital of Philadelphia in the early 1980s.
Subsequently, over a 25-year career, he held a number of leadership positions in clinical and laboratory genetics and metabolism in U.S. medical schools and university hospitals.
The complete list of the ACMG Foundation board of directors is at www.acmgfoundation.org.
About the ACMG Foundation for Genetic and Genomic Medicine
The ACMG Foundation for Genetic and Genomic Medicine, a 501(c)(3) nonprofit organization, is a community of supporters and contributors who understand the importance of medical genetics and genomics in healthcare. Established in 1992, the ACMG Foundation for Genetic and Genomic Medicine supports the American College of Medical Genetics and Genomics' mission to "translate genes into health" by raising funds to help train the next generation of medical geneticists, to sponsor the development of practice guidelines, to promote information about medical genetics, and much more.